Sajjan Rajpoot

5PUBLICATIONS
2CO-AUTHORS
Medical infection agents (incl. prions)Medical molecular engineering of nucleic acids and proteinsGlycoconjugatesCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 02, 2023
Dorzolamide suppresses PKCĪ“ -TIRAP-p38 MAPK signaling axis to dampen the inflammatory response.

Sajjan Rajpoot, Ashutosh Kumar, Vadim Gaponenko

|Aug 08, 2022
Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.

Kundan Solanki, Sajjan Rajpoot, Ashutosh Kumar

|Jul 13, 2022
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.

Tomokazu Ohishi, Takayuki Hishiki, Mirza S Baig

|Apr 07, 2022
Repurposing dyphylline as a pan-coronavirus antiviral therapy.

Yining Wang, Sajjan Rajpoot, Pengfei Li

|Jul 29, 2021
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.

Sajjan Rajpoot, Tomokazu Ohishi, Ashutosh Kumar

Pageof 1

Frequent Collaborators

3 joint publications

Mirza S Baig

1 joint publications

Tomokazu Ohishi